FDA Policy for REMS Reqmts during COVID-19

Health Care, Pharma Industry, Strategic Planning

FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.

Read the Policy now



Related Education Resources.

All Resources

Countdown to Brexit: Can your clinical supply chain pass the Brexit pressure test

Topics: Pharma Industry, Politics

White Paper


2023 EKF Workshop - Logistical Challenges to Clinical Trial Management

Topics: EKF - 2023, Logistics, Supply Chain



Become a member

Global Clinical Supplies Group

Join GCSG for full access...

to our educational resources, conference materials and our directory of more than 480 Clinical Supply colleagues. Experience the culture of collaboration, It only takes approximately 3 minutes 22 seconds.

Please note that membership is included and FREE of charge when you sign up for an event.